Compare British American Tobacco PLC (BTI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs Twist Bioscience Corp — how do they compare? British American Tobacco PLC trades at $56 (market cap $122.36B), while Twist Bioscience Corp trades at $124.01 (market cap $7.72B). The key difference: British American Tobacco PLC is far larger — about 15.8× Twist Bioscience Corp's market cap, and British American Tobacco PLC pays a 5.88% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| BTI | TWST | |
|---|---|---|
Market Cap | $122.36B | $7.72B |
Sector | Consumer Staples | Health |
52-Week High | $66.70 | $124.88 |
52-Week Low | $50.39 | $24.16 |
Enterprise Value | $166.31B | $7.65B |
Dividend Yield | 5.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTI trades at $57.05, down 3.84% in the past 24 hours, with a bearish technical signal but strong fundamentals including a 24.99% net income margin and 13.33% ROE. Recent earnings show three beats out of four quarters, while cash flow turned negative in 2025. The company is pivoting to next-generation nicotine products like Velo, supported by a multi-year tech partnership with ITC Infotech announced in August 2026.
The outlook is mixed: valuation appears reasonable with a P/E of 14.48, and analyst consensus is 66.7% buy ratings, but technical indicators are bearish and regulatory risks persist. The stock offers income potential with dividends, yet faces headwinds from declining combustibles and recent workforce cuts.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
